Home / Transcripts / Prenetics Global Limited (PRE) · February 18, 2026

Prenetics Global Limited (PRE) Earnings Call Transcript

February 18, 2026

NASDAQ US Health Care Health Care Providers and Services earnings 31 min

Earnings Call Speaker Segments

Sheng Wu Yeung executive
#1

Alright, thanks so much. Good morning to all of you, and thank you for joining. This is our call covering results for the fourth quarter and the full year of 2025, so welcome. To those of you who've been tracking what we've been building, I really appreciate the ongoing backing. And if Prenetics is new to you, you're coming in at what we see as a critical turning point. Looking back, 2025 stands out as the year that changed our company more than any other. Revenue hit a record $92.4 million, which represents growth of 480% compared with the prior year, powered by the blockbuster debut of IM8, the premium consumer health brand we launched together with David Beckham as cofounder. Within only our first year, IM8 hit a $120 million annualized revenue run rate — a pace we think ranks among the quickest ever seen in the worldwide supplements sector. On top of that, we carried out a decisive strategic pivot, shedding our noncore assets so that we could become a pure-play leader in consumer health. That move has honed our focus, strengthened our margin profile, and made our balance sheet more solid, which today holds roughly $171 million in total liquidity alongside 0 debt. Above all, we now have a clear road map toward adjusted EBITDA profitability by Q4 of 2027, backed by strong unit economics and meaningful operating leverage. Today I'll take you through our strategic transformation as well as the amazing growth story behind IM8. After that, Stephen will give a detailed rundown of our financial results, and then I'll wrap up with what we expect for 2026 before we open the line for Q&A. Let me start with the transformation that took place during 2025 and into early '26. Our aim was to streamline the company and direct every resource toward the opportunities with the highest growth and highest margin. We accomplished that by divesting 3 noncore assets. Back in June 2025, ACT Genomics was sold for $72 million, with $46 million in cash returning to Prenetics; then in January of '26, we exited the low-margin Europa business through an all-stock $30 million deal. And only yesterday, we announced the sale of our 35% stake in Insighta to Tencent for $70 million in cash, of which $69 million has already landed in our bank accounts. These actions have unlocked considerable shareholder value, simplified our story, and reinforced our financial position. Because of this, our balance sheet is stronger than it has ever been. As of February 15th, 2026, we hold $171.1 million in total adjusted liquid assets, which includes cash, financial assets, and our BTC Holdings, with 0 debt. That gives us plenty of runway to put money into IM8's global expansion. I'd also like to clarify where we stand on Bitcoin. We stopped all Bitcoin purchases as of December 4th, 2025, and we will never again make any Bitcoin or Crypto purchases going forward. Right now we hold 510 BTC on our balance sheet, which adds further financial flexibility as we scale IM8. Our attention is fixed squarely on turning IM8 into a global consumer health powerhouse. Consistent with that strategic focus, we recently announced a change to our Board of Directors. Andy Cheung, who had joined our Board in connection with our Bitcoin strategy, has resigned. We're also very excited to have Dr. Darshan Shah join our Board. Dr. Darshan is a top authority on longevity and performance optimization, and he's also built a network of longevity clinics across the U.S., so his knowledge will be extremely valuable as we take IM8 global. Let's now move on to IM8. Everybody is aware that David Beckham co-founded it with us. IM8 came from the idea of delivering elite, science-backed nutrition to everyone; combining worldwide reach with scientific trust in that way let us reach a $120 million annual recurring run rate in under 12 months. Nothing about this growth path has been ordinary. Q1 stood at $6 million, and Q4 reached $27.4 million. That's not merely a launch spike. It shows strong product market fit for IM8 worldwide, with 40% of revenues generated in the U.S. and 60% generated internationally across 30 different markets. And we got there with outstanding capital efficiency. Across all of our products, including the premium backend stack, our blended LTV to CAC ratio is projected at roughly 3x. For the full year of '25, our payback period came in at only 3.4 months, which lets us recycle marketing capital very quickly. In early 2026, we made a strategic shift toward prioritizing quarterly subscriptions, a new option we offered customers. In our view, this has changed everything. For each new customer, our blended average order value has more than doubled, going from $110 in 2025 to approximately $233 in early 2026. We are deliberately bringing in higher-value customers, which boosts our cash flow and secures predictable revenue over the long term. With 80% of new customers taking a subscription, recurring revenue forms the foundation of our business. The best in the field also validate our brand. We assembled a fantastic Scientific Advisory Board, featuring prominent doctors and professors from the Mayo Clinic, Cedars-Sinai and many others. And our global ambassadors, among them world #1 tennis champion Aryna Sabalenka and recently announced F1 phenom Ollie Bearman, strengthened our credibility in elite performance. Before handing things to Steve, I'd like to share some exciting news regarding investor research. We're pleased to announce that ROTH Capital and Sidoti & Company have both recently begun research coverage of Prenetics, each with buy ratings and 12-month price targets of $36 and $30, respectively; that's a strong validation of our strategy and growth trajectory. And with our momentum and larger market cap, we also anticipate a few additional investment banks will start coverage during the coming quarter. With that, I'll pass the call to our CFO, Stephen Lo, who will go through the financials in more detail. Stephen?

Hoi Chun Lo executive
#2

Thanks, Danny, and good morning to all of you. I'd like to start by walking through what we saw in the fourth quarter. Our total revenue for Q4 jumped 457% compared to the same period a year earlier, reaching $36.6 million, and it rose 55% over Q3 on a sequential basis. The force behind that was IM8, which delivered $27.4 million during Q4. Gross profit for the quarter climbed more than 804%, hitting $21.7 million, with a consolidated gross margin of 59%. Our adjusted EBITDA loss came in at $2.3 million for Q4, which is a 70.4% gain versus the equivalent quarter last year, and that shows how much operating leverage exists in our model as we grow. Turning to the complete year 2025, revenue totaled $92.4 million, roughly 480% above 2024. Gross profit reached $48.9 million, which is an increase of about 428%. For the whole year, adjusted EBITDA loss narrowed by 27%, landing at $13 million. IM8 was plainly the engine here, bringing in $60.1 million of revenue across full year 2025 at a solid 63% gross margin. Once we divest the low-margin Europa business, our consolidated margin profile should improve even more in 2026. As we look forward, we are restating our 2026 guidance with confidence. For full year 2026, we anticipate IM8 revenue somewhere around $180 million to $200 million, which works out to almost 300% growth year-over-year; our target for gross margin in full year 2026 sits at roughly 60%. We also expect our full year 2026 adjusted EBITDA loss to be in the range of about $16 million to $20 million, since we'll keep putting money into marketing to fuel growth, and we see a clear route to reaching adjusted EBITDA profitability by Q4 2027. With that, I'll hand things back to Danny for his closing remarks. Danny?

Sheng Wu Yeung executive
#3

Apologies for that. Yes. Thanks, Stephen. Yes, in short, we've effectively remade Prenetics into a consumer health leader that's growing quickly and is well capitalized. IM8 is clearly on track to turn into a $1 billion global brand. And speaking just for me, across my last 20-plus years as an entrepreneur, working both as an operator and an investor, momentum this powerful in a single brand is something I've never witnessed. The team, the strategy and the financial strength are all in place for us to go after this enormous opportunity, and what lies ahead excites me especially. During Q4 of this year, we intend to unveil 2 new products that will step into very large total addressable markets. Through these launches, our portfolio will become more diversified and our growth trajectory will speed up. My confidence in what's next for Prenetics and IM8 has never been greater. Thanks for being with us today. I'll hand things over now to the operator for Q&A.

George Kelly analyst
#4

Starting with the 90-day offering, I'd like to understand what led to making that available. Also, when should we expect it to start helping your model?

Sheng Wu Yeung executive
#5

Sure, that's a good question. In fact, we launched quarterly subscriptions in the U.S. first, back in December. Usually, what we do is run plenty of tests on our site optimizations every day. So we began testing in the U.S., and after one month of testing it became obvious that, first, consumers truly enjoy this choice. Second, it delivers advantages to both parties. On the consumer side, they receive 3 months of product in one go. Customers also save roughly $10 each month. So for comparison, in the past a typical customer would purchase a 1-month subscription at $89 per month. After the quarterly subscription launched, the price became $78 times 3. That comes to $235 for the quarterly subscription. So we receive that payment upfront. We also cut logistics costs, since rather than sending 3 monthly shipments, we send everything in a single shipment. What that has accomplished is a major lift in our average order value, from about $130 at the end of Q4 to $233. So if you consider each new customer arriving at im8health.com, on average every new subscriber pays us $233. What this means is that it shortens our payback period, or the time it takes to recover our customer acquisition cost. We therefore see this as a major advantage. Meanwhile, consumers now have 3 months of product to try it out. Based on our clinical trial results at 90 days, people will then clearly notice the difference. For instance, 95% of people at 90 days have experienced a notable difference in higher energy levels, better sleep quality, better recovery, greater sleep. So we do think the 90 days will boost retention rates too. All in all, we believe it will be a major improvement for our entire business.

George Kelly analyst
#6

All right, that's useful. Then here's my follow-up, Danny — during your closing comments, you mentioned that 2 new SKUs are arriving this year. I get it if you can't reveal what they are right now, but could you perhaps share a bit more detail regarding when those launches are expected? And how should we think about the new product opportunity in general terms? Would you anticipate that any new product, at least over the short term, resembles your current offerings — meaning a subscription billed monthly? Or could you move into categories that have entirely different product characteristics?

Sheng Wu Yeung executive
#7

Excellent question. Yes. As things stand, we intend to launch 2 new SKUs before this year's Q4 wraps up. Given competitive considerations, we'd rather not disclose prematurely what those 2 SKUs are, though they'll fall within health and performance. And they will certainly sit in the health supplement categories, correct? Additionally, these represent 2 very large total addressable markets, where rivals are already generating somewhere between $500 million and $1 billion each year from these SKUs alone; therefore, we're confident it may serve as a meaningful growth driver for our company.

George Kelly analyst
#8

All right, that helps. Then one last thing from me. About the outlook you gave for IM8 — the $180 million to $200 million for the year — I suppose I have 2 questions there. First, we're already past January and now in February. I was hoping you might shed some light on just the trends you've observed up to this point. January, I think, matters quite a lot for the year. So any commentary on that would be wonderful. And second, do the new products factor into that guidance?

Sheng Wu Yeung executive
#9

Yes, good question, right? So I believe we're still witnessing ongoing momentum. Essentially, momentum hasn't come to a halt on a month-over-month basis, right? As for the 2 new products and how they relate to the revenue guidance, they aren't included in that $180 million to $200 million figure.

Tom Forte analyst
#10

Congrats, Danny, on a fantastic Q4, a fantastic year, and how well IM8 broke out. I've got 3 questions, and I'll ask them one at a time. First: could you discuss what you spend to acquire customers and what they're worth over their lifetime for IM8, and how those figures have moved as time has passed?

Sheng Wu Yeung executive
#11

Sure. On what we pay to acquire a customer — we've actually set all of this out in an investor deck, which we posted to our site, and the press release contains a link to it. Think of it as a return on ad spend of roughly about 0.8x. Say our blended average order for 2025 came to $110 while our CAC was $130. The crucial part here is that it takes about 3.4 months to pay that back, and we take that into account whenever we decide whether to raise spending or hold it steady. Still, since that window is only 3.4 months, we think we've got considerable room to move, going from 3 to 6 months, since within DTC, 3 months counts as excellent and 6 months counts as good. That tells us there's plenty of runway. As for how things have moved, which was your other question: our average order value has climbed a great deal, essentially from $110 to $233, and our CAC has risen alongside it in the very same proportion. So from last January through today, we haven't witnessed any meaningful jump in CAC, even while we scale. One more thing to share: our marketing work, the digital side of it, has centered mainly on Meta and Google — about 85% Meta, 15% Google — and by the close of this quarter and heading into Q2, we'll broaden our marketing channels to bring in YouTube, podcasts, AppLovin, TikTok. So we think we'll also be able to diversify where we market to a much larger degree and with far finer detail.

Tom Forte analyst
#12

Great. For my follow-up, one of the numerous items you've been doing that has really impressed me involves making the most of artificial intelligence. Could you discuss the ways you apply AI, digital marketing included?

Sheng Wu Yeung executive
#13

Sure. That's a wonderful question. I'm a major component — I mean a major advocate of the entire organization adopting the newest AI tools and systems we have available, and not only where digital marketing is concerned, but throughout the company, each function, each individual worker regardless of which department they're in, correct? So my team is aware of this extremely, extremely well, correct? Whatever spare time I personally have, I'm searching — I'm researching AI obsessively, correct? Take, for instance, the way we utilize AI when it comes to digital marketing work each week: we'll introduce somewhere between roughly 800 and 1,000 fresh advertisements. And we simply let the algorithm determine what succeeds. Then merely around 10% of those advertisements will truly succeed. We refer to those as a winning ad. After that, each week, we duplicate essentially — we take 10% of the ones that succeed, and we duplicate an additional 800 advertisements every week. So that provides you a single illustration of essentially the way we apply AI. And naturally, I believe if you check the investor deck, you'll likewise notice we introduced an AI video last September alongside Aryna Sabalenka just ahead of the U.S. open. And this single AI video, it essentially — it had the largest count of views of any brand on Instagram; it achieved 233 million views from one AI video starring Aryna Sabalenka. So once you obtain 233 million views from a single video at the top of funnel, you can then far more easily we target new other customers who have watched that video, correct? So I believe those are particular illustrations of the way we're leveraging ad. We employ AI across every part of our business.

Tom Forte analyst
#14

Fantastic, and now the final question from my side. You've successfully shed quite a few thriving companies. Your balance sheet is truly remarkable. Given that, could you share your approach to strategic M&A — how you decide, and when it's better to create something yourself rather than acquire it?

Sheng Wu Yeung executive
#15

Yes, Kirk. Yeah, I'd say 2025 turned out to be an incredibly hectic year, correct? You can observe that we didn't just establish a highly robust operation, and that was done from nothing, right? That was grown organically by us — the entire brand, the playbook, every doctor, every scientist, every brand ambassador, and naturally, the product itself, right? Simultaneously, we carried out the sale of 3 of our noncore assets since IM8's expansion was simply so extraordinary that we understood we had to double down on it, right? And so at this point we possess a really solid balance sheet. I mean, the truth is that an enormous number of choices are open to us. However, I'd say my initial — our primary emphasis will be on growing organically, because, once more, we think we already have this performance marketing flywheel supporting us, unless a highly strategic M&A possibility appears. At present, what we're mostly concentrated on is simply expanding organically, because, again, that's something within our strong control; yet, once more, we remain open to fresh opportunities whenever it's sensible.

Alex Hantman analyst
#16

Nice work on the quarter. Perhaps we can begin with this year's revenue growth. You said new products aren't included in that figure. Could you tell us more about what portion of the growth should come from expanding the customer base, and what portion from higher average revenue per user driven by quarterly plans?

Sheng Wu Yeung executive
#17

I'd put it this way — the growth basically comes from — most of it will come from new customers, correct? Consider that we hit $60 million in full year revenue during our first year, and the brand is still quite new. So this year — although plenty of people know about IM8, a large population globally still hasn't heard of IM8, or hasn't tried or used the product, right? And after people try the product, use the product, again, since the product works, they'll stay on; so a big chunk of that growth will come from new customers. And looking at our breakdown across our top 5 markets, with the U.S. at #1, 40% of revenue. Last year, the U.S. accounted for only $23 million out of $60 million, right? So I think realistically, the U.S. market can easily support or absorb yes, $300 million to $400 million from this one product, right? So there's still plenty of headway, plenty of runway ahead, right? Canada is #2, the U.K. is #3, Australia is #4, and Singapore is #5, right? So we're a genuinely global, diversified brand; so we believe there's a major opportunity simply by bringing new customers onto the platform.

Alex Hantman analyst
#18

That's helpful background. We have two additional items. Dan, you mentioned earlier some of the chances to earn revenue abroad. As you began adapting websites for other locales, what sort of revenue gain have you observed? And with that in mind, which market outside the US gets you most enthusiastic?

Sheng Wu Yeung executive
#19

Yeah. Excellent question, correct? So once more this illustrates the way we are currently applying AI resources, in particular to our efforts at localizing internationally; thus before the close of Q2 this year, we'll be adapting our full site, our advertising, and our campaigns across no fewer than 5 separate markets — Germany being one instance, correct? So many of those ads — Germany currently ranks, I believe, #8 or #9 among the world's leading markets. For such markets, our expectation is that adapting our complete website will yield no less than a 10% to 15% gain within local markets, correct? And so, once again, that's a thing we intend to roll out before Q2 arrives, in fact probably before this quarter ends.

Alex Hantman analyst
#20

Great. And this will be our final one. You referenced the goal of reaching EBITDA profitability by Q4 2027. Could you walk us through a few of the main drivers behind getting there — things like marketing leverage, scale, and product mix? And is there an EPS target that goes along with it?

Sheng Wu Yeung executive
#21

Yes. So again, I'd say that as we grow, and since our gross margin sits at 60%, profitability follows from that, correct? That means once we reach $250 million, $300 million in revenue, we'll have far more leverage available to us, because our manufacturers, our suppliers, our logistics are already in place; so we're confident that over the next 12 to 18 months we can even gradually push our margins upward from 60% to 62%, 63%, correct? So that, combined with scale, should then carry us — we believe — to profitability by the end of Q4 2027. Essentially it's just continuing what we're doing today, but at a far larger scale. And naturally, all the costs get absorbed, okay?

Sheng Wu Yeung executive
#22

Alright. I appreciate all of you being here on this call today. Once more, my enthusiasm for what lies ahead couldn't possibly be greater. As was noted, I've spent over 20 years as an entrepreneur, yet this venture is one I feel deeply driven to pursue — creating a worldwide brand that touches the lives of millions across the globe. Tremendous backing comes to us from many corners of the world, including very prominent athletes, physicians, and academics, which makes traveling this path such a joy. So once again, my thanks to each of you for spending time with us today.

Operator operator
#23

Everyone, we appreciate you joining us. That brings today's conference call to a close. Please feel free to hang up your phones, and enjoy the rest of your day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Prenetics Global Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Prenetics Global Limited earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.